Jejunostomy in the palliative treatment of gastric cancer: A clinical prognostic score

Table 1 Variables and points for each category-risk score for 90-d mortality

Variables	Category	Points
Sex	Female	7
Age (years)	≥ 65	4
BMI (kg/m2)	BMI < 18.5	1
CCI	CCI ≥ 1	7
ASA classification	III/IV	9
Hb (g/dL)	Hb ≤ 11	1
Alb (g/dL)	Alb < 3.5	3
NLR	NLR ≥ 2.5	50
Presence of ascites on CT	Present	5
Tumor size (cm)	> 7 cm	5
Number of disease sites	Two or more	8
Total		100

CCI: Charlson's comorbidity index; CT: Computed tomography; NLR: Neutrophil lymphocyte ratio; ASA: American Society of Anesthesiologists; BMI: Body mass index; Hb: Hemoglobin; Alb: Albumin.

Table 2 Characteristics of jejunostomy patients according to the risk group-score development cohort (n = 40)

Variables	J1-score development cohort		P value
	Low-risk	High-risk
	n = 14 (%)	n = 26 (%)
Sex			0.507
Female	6 (42.9)	14 (53.8)
Male	8 (57.1)	12 (46.2)
Age (years)			0.954
mean (SD)	62.0 (15.0)	61.7 (12.9)
BMI (kg/m2)			0.101
mean (SD)	20.4 (2.7)	22.4 (3.9)
CCI			0.885
0	10 (71.4)	18 (69.2)
≥ 1	4 (286)	8 (30.8)
ASA class			0.507
I/II	8 (57.1)	12 (46.2)
III/IV	6 (42.9)	14 (53.8)
Hemoglobin (g/dL)			0.456
mean (SD)	11.1 (1.9)	10.5 (2.0)
Albumin (g/dL)			0.123
mean (SD)	3.7 (0.6)	3.3 (0.6)
NLR			0.001
mean (SD)	3.03 (1.58)	7.46 (5.22)
Tumor size (cm)			0.18
mean (SD)	6.9 (2.1)	8.3 (3.4)
Presence of ascites on CT			0.48
Absent	6 (42.9)	7 (26.9)
Present	8 (57.1)	19 (73.1)
Lauren type			1
Intestinal	4 (28.6)	6 (23.1)
Diffuse/mixed	9 (64.3)	17 (65.4)
Undetermined	1 (7.1)	3 (11.5)
Number of disease sites			0.408
One (only locoregional)	6 (42.9)	7 (26.9)
Two or more	8 (57.1)	19 (73.1)
POC			0.075
No POC/Clavien 1-2	14 (100)	19 (73.1)
Clavien 3-5	0 (0)	7 (26.9)
Length of hospital stay (days)			0.452
Median (IQR)	4.5 (1.7-6.3)	5 (2.7-9.5)
Palliative treatment-1st line			0.257
No	6 (42.9)	16 (61.5)
Yes	8 (57.1)	10 (38.5)
30-d mortality			0.013
No	13 (92.9)	13 (50)
Yes	1 (7.1)	13 (50)
90-d mortality			< 0.001
No	12 (85.7)	7 (26.9)
Yes	2 (14.3)	19 (73.1)

SD: Standard deviation; IQR: Interquartile range; POC: Postoperative complication; CCI: Charlson's comorbidity index; CT: Computed tomography; NLR: Neutrophil lymphocyte ratio; ASA: American Society of Anesthesiologists; BMI: Body mass index.

Table 3 Characteristics of jejunostomy patients according to the risk group-score validation cohort (n = 40)

Variables	J2-score validation cohort		P value
	Low-risk	High-risk
	n = 21 (%)	n = 19 (%)
Sex			0.721
Female	6 (28.6)	4 (21.1)
Male	15 (71.4)	15 (78.9)	0.072
Age (years)
mean (SD)	59.7 (12.4)	66.7 (11.4)
BMI (kg/m2)			0.074
mean (SD)	21.4 (3.5)	19.0 (4.7)
CCI			0.001
0	21 (100)	11 (57.9)
≥ 1	0 (0)	8 (42.1)
ASA class			0.002
I/II	16 (76.2)	5 (26.3)
III/IV	5 (23.8)	14 (73.7)
Hemoglobin (g/dL)			0.345
mean (SD)	11.4 (2.3)	10.6 (2.4)
Albumin (g/dL)			0.047
mean (SD)	3.6 (0.6)	3.1 (0.6)
NLR			0.012
mean (SD)	3.65 (3.45)	8.81 (7.64)
Tumor size (cm)			0.731
mean (SD)	6.6 (2.6)	6.9 (3.4)
Presence of ascites on CT			0.004
Absent	14 (66.7)	4 (21.1)
Present	7 (33.3)	15 (78.9)
Lauren type			0.753
Intestinal	5 (23.8)	7 (36.8)
Diffuse/mixed	13 (61.9)	9 (47.4)
Undetermined	3 (14.3)	3 (15.8)
Number of disease sites			0.385
One (only locoregional)	7 (33.3)	4 (21.1)
Two or more	14 (66.7)	15 (78.9)
POC			1
No POC/Clavien 1-2	19 (90.5)	17 (89.5)
Clavien 3-5	2 (9.5)	2 (10.5)
Length of hospital stay (days)			0.455
Median (IQR)	3 (3-7.5)	4 (4-8)
Palliative treatment-1st Line			0.012
No	5 (23.8)	12 (63.2)
Yes	16 (76.2)	7 (36.8)
30-d mortality			0.049
No	18 (85.7)	11 (57.9)
Yes	3 (14.3)	8 (42.1)
90-d mortality			0.027
No	14 (66.7)	6 (31.6)
Yes	7 (33.3)	13 (68.4)

SD: Standard deviation; IQR: Interquartile range; POC: Postoperative complication; CCI: Charlson's comorbidity index; CT: Computed tomography; NLR: Neutrophil lymphocyte ratio; ASA: American Society of Anesthesiologists; BMI: Body mass index.